Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics (RVVTF) has provided an update on its research study of Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC). The study is scheduled to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation. Positive results could lead to human clinical trials in the second half of 2025, seeking FDA and Health Canada approvals for nerve agent and organophosphate pesticide poisoning treatment.
Bucillamine, which is a more potent antioxidant than n-acetylcysteine (NAC), shows potential in protecting GABA(A) receptors and improving anticonvulsant therapies' effectiveness while reducing bleeding risks associated with NAC. The research also explores Bucillamine's applications in traumatic brain injury and viral infections.
Revive Therapeutics (RVVTF) ha fornito un aggiornamento sullo studio di ricerca su Bucillamina come possibile trattamento per l'esposizione ad agenti nervini, condotto in collaborazione con il Defence R&D Canada – Suffield Research Centre (DRDC). Lo studio è previsto terminare entro giugno 2025, concentrandosi sugli anticorpi del recettore GABA e sulla conferma dei dati. Risultati positivi potrebbero portare a trial clinici sull’uomo nella seconda metà del 2025, con l’obiettivo di ottenere l’approvazione della FDA e di Health Canada per il trattamento dell’avvelenamento da agenti nervini e pesticidi organofosfati.
La Bucillamina, un antiossidante più potente rispetto alla n-acetilcisteina (NAC), mostra potenzialità nella protezione dei recettori GABA(A) e nel migliorare l’efficacia delle terapie anticonvulsivanti, riducendo al contempo i rischi di sanguinamento associati alla NAC. La ricerca esplora inoltre le applicazioni della Bucillamina nel trattamento del trauma cranico e delle infezioni virali.
Revive Therapeutics (RVVTF) ha proporcionado una actualización sobre su estudio de investigación de Bucilamina como posible tratamiento para la exposición a agentes nerviosos, realizado en colaboración con el Defence R&D Canada – Suffield Research Centre (DRDC). El estudio está programado para concluir en junio de 2025, centrado en los anticuerpos del receptor GABA y la confirmación de datos. Resultados positivos podrían conducir a ensayos clínicos en humanos en la segunda mitad de 2025, buscando la aprobación de la FDA y Health Canada para el tratamiento del envenenamiento por agentes nerviosos y pesticidas organofosforados.
La Bucilamina, un antioxidante más potente que la n-acetilcisteína (NAC), muestra potencial para proteger los receptores GABA(A) y mejorar la eficacia de las terapias anticonvulsivas mientras reduce los riesgos de sangrado asociados con la NAC. La investigación también explora las aplicaciones de la Bucilamina en lesiones cerebrales traumáticas e infecciones virales.
Revive Therapeutics (RVVTF)는 Defence R&D Canada – Suffield Research Centre (DRDC)와 협력하여 신경 작용제 노출 치료제로서의 부실라민 연구 진행 상황을 업데이트했습니다. 이 연구는 2025년 6월까지 완료될 예정이며, GABA 수용체 항체 및 데이터 확인에 중점을 두고 있습니다. 긍정적인 결과가 나오면 2025년 하반기에 인간 임상 시험으로 이어질 수 있으며, 신경 작용제 및 유기인계 살충제 중독 치료를 위해 FDA 및 캐나다 보건부 승인을 목표로 하고 있습니다.
부실라민은 N-아세틸시스테인(NAC)보다 더 강력한 항산화제로, GABA(A) 수용체를 보호하고 항경련제 치료의 효과를 향상시키는 동시에 NAC와 관련된 출혈 위험을 줄이는 잠재력을 보여줍니다. 이 연구는 또한 외상성 뇌손상 및 바이러스 감염에 대한 부실라민의 적용 가능성도 탐구하고 있습니다.
Revive Therapeutics (RVVTF) a fourni une mise à jour sur son étude de recherche concernant la Bucillamine en tant que traitement potentiel contre l'exposition aux agents neurotoxiques, menée en partenariat avec le Defence R&D Canada – Suffield Research Centre (DRDC). L'étude devrait se terminer d'ici juin 2025, en se concentrant sur les anticorps des récepteurs GABA et la confirmation des données. Des résultats positifs pourraient mener à des essais cliniques humains au second semestre 2025, dans le but d'obtenir les approbations de la FDA et de Santé Canada pour le traitement des intoxications aux agents neurotoxiques et aux pesticides organophosphorés.
La Bucillamine, un antioxydant plus puissant que la N-acétylcystéine (NAC), montre un potentiel pour protéger les récepteurs GABA(A) et améliorer l'efficacité des thérapies anticonvulsivantes tout en réduisant les risques de saignement associés à la NAC. La recherche explore également les applications de la Bucillamine dans les traumatismes crâniens et les infections virales.
Revive Therapeutics (RVVTF) hat ein Update zu seiner Forschungsstudie über Bucillamin als potenzielle Behandlung bei Nervengift-Exposition veröffentlicht, die in Zusammenarbeit mit dem Defence R&D Canada – Suffield Research Centre (DRDC) durchgeführt wird. Die Studie soll bis Juni 2025 abgeschlossen sein und konzentriert sich auf GABA-Rezeptor-Antikörper und Datenbestätigung. Positive Ergebnisse könnten in der zweiten Hälfte des Jahres 2025 zu klinischen Studien am Menschen führen, mit dem Ziel, Zulassungen der FDA und Health Canada für die Behandlung von Vergiftungen durch Nervengifte und organophosphathaltige Pestizide zu erhalten.
Bucillamin, ein stärkeres Antioxidans als N-Acetylcystein (NAC), zeigt Potenzial, GABA(A)-Rezeptoren zu schützen und die Wirksamkeit von Antikonvulsiva zu verbessern, während es das mit NAC verbundene Blutungsrisiko verringert. Die Forschung untersucht zudem die Anwendungsmöglichkeiten von Bucillamin bei traumatischen Hirnverletzungen und Virusinfektionen.
- Potential FDA and Health Canada approvals pathway identified for H2 2025
- Bucillamine shows superior antioxidant properties compared to NAC with reduced bleeding risks
- Partnership with Defence R&D Canada adds credibility and resources to the research
- Multiple potential applications including nerve agent exposure, traumatic brain injury, and viral infections
- Study still in early research phase with no human trial data yet
- Results and timeline dependent on June 2025 study conclusion
- No guarantee of positive study outcomes or regulatory approvals
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which brings a wealth of expertise and resources to the project. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury.
After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation for effect size. Positive outcomes may accelerate human clinical trials in the second half of 2025, aiming for FDA and Health Canada approvals for treating nerve agent or organophosphate pesticide poisoning. Additionally, Bucillamine’s potential in traumatic brain injury from concussive/explosive forces and viral infections is under exploration.
Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and six months ended December 31, 2024 ("MD&A"), dated February 24, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
When will Revive Therapeutics (RVVTF) complete its Bucillamine nerve agent study?
What advantages does Bucillamine have over NAC for nerve agent treatment?
When could Revive Therapeutics begin human trials for Bucillamine in nerve agent exposure?
What conditions could Bucillamine potentially treat according to RVVTF's research?
Who is partnering with Revive Therapeutics on the Bucillamine nerve agent study?
